April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Resolution Of Foveal Cystoid Changes In Idiopathic Juxtafoveal Telangiectasis With Carbonic Anhydrase Inhibitors
Author Affiliations & Notes
  • John J. Chen
    Ophthalmology, University of Iowa, Iowa City, Iowa
  • Culver Boldt
    Ophthalmology, University of Iowa, Iowa City, Iowa
  • James C. Folk
    Ophthalmology, University of Iowa, Iowa City, Iowa
  • Vinit B. Mahajan
    Ophthalmology, University of Iowa, Iowa City, Iowa
  • Stephen R. Russell
    Ophthalmology, University of Iowa, Iowa City, Iowa
  • Elliott H. Sohn
    Ophthalmology, University of Iowa, Iowa City, Iowa
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4522. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      John J. Chen, Culver Boldt, James C. Folk, Vinit B. Mahajan, Stephen R. Russell, Elliott H. Sohn; Resolution Of Foveal Cystoid Changes In Idiopathic Juxtafoveal Telangiectasis With Carbonic Anhydrase Inhibitors. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4522.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Idiopathic juxtafoveal telangiectasis (IJT) is an uncommon disease characterized by telangiectatic vessels in the juxtafoveolar region of one or both eyes. There is currently no treatment and the natural progression of the disease results in significant visual loss in the majority of patients. Recent studies have demonstrated that carbonic anhydrase inhibitors (CAIs) are effective in the treatment of macular edema associated with retinitis pigmentosa and x-linked retinoschisis and may improve visual function in these diseases. Patients with IJT also often have subfoveal cystoid changes. This study evaluates the effect of CAIs in the treatment of IJT.

Methods: : Retrospective review of all patients with the diagnosis of IJT seen between 1990-2010 at a university hospital. The age, gender, presenting and final visual acuity, treatments, and optical coherence tomography results (including central macular thickness and presence of cystoid changes in the macula) were recorded.

Results: : CAIs were used in seven eyes of four patients with IJT. Two patients were treated with topical dorzolamide and two patients were treated with systemic methazolamide. Four of seven eyes had resolution of cystoid changes. Visual acuity improved in two eyes from two separate patients, one treated with topical dorzolamide and one treated with methazolamide. Improvement was seen within two months and maintained for two and three years, respectively. Two eyes had no change in visual acuity. Three eyes had a gradual worsening of visual acuity. Follow-up ranged between 1 to 9 years.Nine eyes of five patients with IJT were identified that did not receive treatment. Visual acuity decreased in five eyes and remained stable in four eyes, with follow-up between 1 to 11 years. There was no improvement in visual acuity or changes in cystic spaces in any of the patients that did not receive treatment.

Conclusions: : Carbonic anhydrase inhibitors, both topical and systemic, may decrease the macular cystoid changes seen in IJT that could correspond to improvement in visual acuity.

Keywords: carbonic anhydrase • macula/fovea • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×